Abstract：OBJECTIVE To analyze the main measures of the drug quality and safety risks management in the national drug sampling and testing, and provide reference for improving the drug sampling and testing after listing. METHODS Using retrospective research methods to analyze the effects of the deadline management, special item (special topic) sampling and testing, serious quality risk disposal mechanism, nonserious quality risk warning mechanism, information disclosure on drug quality and safety risk management during the national drug sampling and testing in 2014-2019. RESULTS A series of measures improved a timely, efficient and complete closed-loop response chain of risk identification-disposal-disclosure. CONCLUSION The main measures can help reduce public drug safety risks and have good demonstration and guiding significance for local drug sampling and testing. It is recommended to continuously improve the risk management mechanism, such as learning from the US and EU drug regulatory experience, strengthening the sampling and testing of vaccines, imported drugs and consistency evaluated drugs, and personalized designing test and research strategies.
刘文, 朱炯, 王翀. 国家药品抽检风险管理主要举措分析与建议[J]. 中国药学杂志, 2020, 55(16): 1394-1398.
LIU Wen, ZHU Jiong, WANG Chong. Analysis and Suggestions on Main Measures of Risk Management in National Drug Sampling and Testing. Chinese Pharmaceutical Journal, 2020, 55(16): 1394-1398.
ZHU J L, JIANG D C, ZHANG C, et al. Improvement and perfect for the model marketed drug sampling and testing for quality evaluation--preliminary discussion on the drug quality study. Chin J Pharm Anal(药物分析杂志), 2009, 29( 10) : 1765-1767.
[2]
CHINA FOOD AND DRUG ADMINISTRATION. Unannounced Inspection of Shanxi Momeide Pharmaceutical Co., Ltd. . (2014-10-23) http://www. nmpa. gov. cn/WS04/CL2065/321499. html.
[3]
LI Y P, WEN J, WANG L. Risk management of drugs: concepts, principles, methodology and practice. Chin J Evid-Based Med (中国循证医学杂志), 2007, 7(12): 843-848.
YAO K H, JIA J. Enhance research, prevention and control of pertussis for protecting public confidence in vaccination: focus on the adverse events of vaccine with insufficient potency and its long-term impacts. Chin J Contemp Pediatr(中国当代儿科杂志),2018, 20(1):1-4.
[6]
LI C Y, ZHI X L, NIU X Y, et al. Removing bacterial endotoxin from glycyrrhizic acid for injection by ultrasonic-assisted ultrafiltration technology. Chin Pharm J (中国药学杂志), 2019, 54(22): 1888-1894.
[7]
ZHANG Y, CAI T, WU Y L. Suitability of human whole blood in vitro pyrogen test for meningococcal groups ACYW135 polysaccharide vaccine. Chin Pharm J (中国药学杂志), 2015, 50(11): 983-986.
[8]
WANG J C, HE J Q,HU Z Y. Second Discussion on the Construction of a “National Defense System” for Post-market Drug Supervision: An Exploratory Study of Drug Sampling and Testing . China Pharmaceutical News(中国医药报), 2019-04-29(3).
[9]
WANG C, CHENG S H. Analysis and suggestion on effect of drug safety regulatory during national drug sampling and testing. Chin Pharm J(中国药学杂志), 2016,51(20):1815-1818. LI Y D. Application of time management in improving government administrative efficiency. J Liaoning Admin Coll(辽宁行政学院学报), 2014,16(5):18-19. NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL. National Drug Sampling and testing Annual Report (2016). (2017-10-09) http://www. nifdc. org. cn/nifdc/fwzn/ypchytsxyj/9872. html. NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL. National Drug Sampling and testing Annual Report(2017) . (2018-06-05) http://www. nifdc. org. cn/nifdc/fwzn/ypchytsxyj/11119. html. NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL. National Drug Sampling and testing Annual Report(2018) . (2018-08-07) https://www. nifdc. org. cn/nifdc/fwzn/ypchytsxyj/20190807101035. html. CHINA FOOD AND DRUG ADMINISTRATION. Announcement on the illegal production of new compound daqingye tablets by 6 pharmaceutical manufacturers (No.96 in 2015) .(2015-12-02) . http://www.nmpa.gov.cn/WS04/CL2138/300080.html. CHEN G, WANG R F, XIONG X L. Analysis on the perfection of China's drug safety information disclosure system . J Jiangxi Univ Tradit Chin Med(江西中医药大学学报),2014, 26(1): 75-78. ZHU J, JIANG H, HU Z Y. Third Discussion on Construction of "National Defense System" for Post-market Drug Supervision. China Pharmaceutical News(中国医药报), 2019-06-25(3). 110th Congress. Food and Drug Administration Amendments Act of 2007. (2007-09-27) . https: //www.congress.gov/110/plaws/publ85/PLAW-110publ85.pdf. EUROPEAN MEDICINES AGENCY. 20 years of Sampling and Testing of Centrally Authorised Products 1998-2017 . (2019-03-28) https://www. ema. europa. eu/en/search/search? search_api_views_ fulltext=1998-2017. QANG X X,WANG J J,ZHAO Y, et al. Application of quality by design (QbD) to development of liposomes. Chin J Pharm(中国医药工业杂志), 2018,49(12):1636-1643.
2020, Vol. 55 
